BSX Stock Faces Watchman Reset As Analysts Slash Targets

Boston Scientific Corporation stocks have been trading up by 6.04 percent after promising clinical results boosted investor optimism.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading BSX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways For BSX Traders

Bank of America cut its price target on Boston Scientific from $68 to $61 but kept a Buy rating, flagging procedure pressure and inflation-hit medtech margins into 2027.
Truist reduced its price target from $85 to $64 while reiterating a Buy, still projecting at least 7% revenue growth and double‑digit EPS growth despite slowing U.S. Watchman momentum.
BTIG cut its BSX target from $80 to $65, modeling flat Watchman sales in Q2–Q3, a small Q4 uptick, and a gradual recovery into 2027 after softer guidance from management.
Jefferies lowered its Boston Scientific target to $67 from $100, slashing 2026 U.S. Watchman growth expectations from 14% to 5% on market changes and mixed CHAMPION data.
Despite broad target cuts from multiple firms, BSX still carries a consensus Buy rating with average price targets in the mid‑$70s, implying upside from current levels.

Live Update At 12:33:02 EDT: On Thursday, July 02, 2026 Boston Scientific Corporation stock [NYSE: BSX] is trending up by 6.04%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

BSX has been grinding higher after a sharp pullback. The daily chart shows Boston Scientific bouncing from the low‑$40s to a recent close around the mid‑$40s, with the latest session finishing near $45.67 after a strong intraday trend up from the $43s. That’s a clean show of dip‑buying demand.

Zoom in and the 5‑minute chart for BSX is basically a stair‑step move. Early weakness around $43.70 attracted buyers, then the stock pushed steadily to new intraday highs above $45.50. For short‑term trading, that intraday higher‑low pattern is classic momentum‑long territory, especially when volume confirms.

More Breaking News

Fundamentally, Boston Scientific is not trading like a broken story. Revenue sits around $20.07B with three‑ and five‑year growth in the mid‑teens, backed by a strong 69.2% gross margin and nearly 20% EBIT margin. BSX carries a P/E of 24.1 and a price‑to‑sales near 4.2 — not cheap, but in line with a quality medtech grower. Debt looks manageable with total debt‑to‑equity at 0.43 and a current ratio of 1.9. For traders, that backdrop supports the idea that recent volatility in BSX is more about expectations resetting than balance sheet stress.

Why Traders Are Watching BSX’s Watchman Reset

The real drama around BSX right now is not whether Boston Scientific is profitable. It is how fast one of its core growth engines — the Watchman left atrial appendage closure franchise — can keep growing from here.

Truist cut its BSX price target from $85 to $64, pointing to near‑term slowing U.S. Watchman growth. Yet Truist still expects at least 7% revenue growth and double‑digit EPS growth. That tells traders the growth story is cooling, not collapsing. When a stock re‑rates from hyper‑growth expectations to “solid compounder,” the chart often gets choppy as funds rebalance.

BTIG went a step further and laid out a timeline. After talking with Boston Scientific management, BTIG now models flat Watchman sales in Q2–Q3, a small uptick in Q4, and a gradual rebuild into 2027. For BSX traders, that’s a roadmap: sideways fundamentals near term, then a slow grind higher. Short‑term players may fade spikes during the flat phase; swing traders may stalk those transition points into the expected recovery.

Stifel’s channel checks add more color. Doctors cited operating room capacity limits, some pushback to new clinical data, and pockets of site‑of‑care saturation. Jefferies slashed its 2026 U.S. Watchman growth forecast from 14% to 5% and chopped the BSX target from $100 to $67. That is a serious reset in expectations for Boston Scientific.

Yet, across Wall Street, BSX still holds a consensus Buy with average targets in the mid‑$70s — well above today’s mid‑$40s handle. Piper Sandler, Bank of America, BTIG, Stifel, Jefferies, and Truist all cut targets on Boston Scientific while keeping positive ratings. That combo — lowered bar, still‑bullish stance — is exactly the kind of “fallen favorite” setup momentum traders stalk once the selling pressure exhausts.

Conclusion

For Boston Scientific, this is what a sentiment reset looks like. BSX has seen a string of price‑target cuts: BofA down to $61 on macro margin worries, Truist to $64, BTIG and Stifel to $65, Jefferies to $67, and Piper Sandler also sitting at $65. The common thread is clear. Analysts are dialing back Watchman and long‑term top‑line assumptions, but they are not abandoning the story.

Under the hood, BSX still posts strong margins, steady double‑digit earnings growth, and a clean balance sheet. The chart shows buyers stepping in around the low‑$40s and pushing Boston Scientific back toward the mid‑$40s even as headlines scream about cuts. That divergence between fear in the news and strength on the tape is something active traders should respect.

There is also a near‑term catalyst. Boston Scientific management is meeting BTIG in New York on 2026/06/23. Any fresh color on Watchman utilization, CHAMPION data interpretation, or operating room bottlenecks can swing BSX quickly.

For traders, the play is not about believing any single Wall Street target. It is about mapping the expectations cycle and managing risk around shifting expectations. As Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.” Right now, the bar for Boston Scientific is lower, but still positive. As Tim Sykes loves to say, “Patterns repeat because human nature doesn’t change.” BSX is moving from hype to hesitation — and that’s often where disciplined, prepared trading thrives, for educational and research purposes only and never as investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!